FINWIRES · TerminalLIVE
FINWIRES

在 Campo Morado 钻探结果公布后,Stifel Canada 维持对 Luca Mining 的“买入”评级;目标价维持在 4.00 加元。

By

-- 周三,Stifel Canada维持对Luca Mining(LUCA.V)股票的“买入”评级,目标价为4.00加元。此前,该公司公布了其位于墨西哥Campo Morado矿的钻探结果。 Luca报告称,Campo Morado的Largo Norte矿区地下钻探结果显示,加权平均金品位为2.05克/吨,比Campo Morado目前矿区探明的金品位1.70克/吨高出约20%。现有地下基础设施附近的多金属矿化带表明,随着钻探将矿化范围扩展到现有资源边界之外,该矿区具有以较低资本密集度开采的潜力。我们认为,这些结果支持Campo Morado即将发布的2026年下半年矿山寿命周期(LoM)计划更新和扩建研究,该研究概述了通过提高产量和回收率,将集团产量从2026年的约5.5万盎司/年金当量提高到2029年的约11万盎司/年金当量的潜在路径。Campo Morado的长期市净率(LT P/NAV)为0.23倍,而同业小型矿业公司为0.57倍;2026年市现率(P/CF)为5.4倍,而同业小型矿业公司为7.8倍。鉴于Campo Morado扩建项目和即将发布的矿山计划更新,我们仍然认为Campo Morado具有多重扩张潜力。分析师科尔·麦吉尔写道:“提高卢卡增长前景的可见度。” (报道北美、亚洲和欧洲主要银行及研究机构的股票、商品和经济研究。研究机构可通过以下链接联系我们:https://www..com/contact-us

Price: $1.33, Change: $-0.04, Percent Change: -2.92%

Related Articles

Research

Research Alert: CFRA Downgrades Rating To Sell From Hold On Shares Of Essex Property Trust, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target by $15 to $250 using a narrower equity risk premium and a forward P/FFO of 15.5x, which is in line with the multifamily residential REIT average. We keep our 2026 FFO estimate at $16.15 and lower 2027's by $0.05 to $16.45 on respective revenue projections of $1.94B and $1.98B. Rental revenue is not yet rebounding to historical growth levels. Across the industry, we are seeing inflation in key operating expenses exceeding revenue growth, and this leads to modest gains in cash NOI growth Y/Y. We expect these market conditions to continue as pricing power for ESS and its peers seems to have eased. In particular, ESS has a West Coast portfolio profile that is exposed to significant job layoffs in the technology sector. In our opinion, we have not yet seen the tail risk of major announcements just released in recent weeks. ESS has the challenge of complying with strict housing guidelines in California, leading to the trust historically underperforming peers in other parts of the country.

$ESS
Research

Research Alert: CFRA Keeps Buy Rating On Shares Of Biogen Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our target at $236, 13.8x our new 2027 EPS view, a discount to BIIB's five-year historical forward P/E average of 14.1x. We lower our 2026 EPS view to $15.24 from $16.14 to adjust for the impact from acquired IPR&D. We keep our 2027 EPS view at $17.16. BIIB reported a strong start to 2026, with sales of $2.5B and adjusted EPS of $3.57. We see a successful stabilization of the business after years of decline, due to a 12% Y/Y increase in the growth products portfolio. In our view, during the analyst call, management presented a clear strategic vision centered on the pending $5.6B acquisition of Apellis, expected to close in Q2, which can transform BIIB into a growth company by adding two commercial assets, Syfovre and Empaveli. We think the Apellis deal could bridge a revenue gap until 2028, when the company's late-stage pipeline matures. Via this acquisition, BIIB also gains nephrology expertise and an established infrastructure, which could set its key asset Felzartamab launch for success.

$BIIB
Australia

Starbucks to Sustain Sales Momentum; to Focus on Margins in H2, UBS Says

Starbucks (SBUX) is expected to maintain solid sales momentum on its turnaround strategy, though investor focus is shifting toward margin recovery in H2, UBS said in a note on Wednesday.The brokerage said strong transaction-driven comparable sales growth in Q2 reflected improvements in operations, menu innovation and updated loyalty program.Looking ahead, UBS said continued execution on initiatives such as afternoon beverage platforms, loyalty enhancements, store closures and operational improvements should support sales into H2.UBS also expects margin expansion later in the year, supported by sales leverage, cost savings and easing pressures from tariffs and coffee costs.UBS raised the price target on the stock to $105 from $100 but maintained a neutral rating.Price: $106.10, Change: $+8.82, Percent Change: +9.06%

$SBUX